Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Evolus

< Previous 1 2 3 Next >
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Second Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report Second Quarter 2023 Results and Provide Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports First Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in the Barclays Global Healthcare Conference
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus Not Affected by Recent Korean Court Ruling
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in the SVB Securities Global Biopharma Conference
From Evolus
Via Business Wire
Tickers EOLS
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
From Evolus
Via Business Wire
Tickers EOLS
Evolus Receives Regulatory Approval for Nuceiva® in Australia
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
From Evolus
Via Business Wire
Tickers EOLS
Evolus Extends Term of Credit Facility with Pharmakon Advisors
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Third Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in November Conferences
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report Third Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain
From Evolus
Via Business Wire
Tickers EOLS
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Inducement Grants for New Chief Financial Officer
From Evolus
Via Business Wire
Tickers EOLS
Evolus Appoints Sandra Beaver as Chief Financial Officer
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Evolus
Via Business Wire
Tickers EOLS
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Second Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report Second Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
From Evolus
Via Business Wire
Tickers EOLS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.